All In Biotech

Drug Trial Radar · NCT07070999

Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1

A Phase 1-2, Open-Label, Multicenter Study to Assess the Safety, Tolerability and Efficacy of a Single Dose of GB221 Delivered Into the Cisterna Magna of Pediatric Participants From 2 Weeks to Younger Than 12 Months of Age With Spinal Muscular Atrophy Type 1

Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

22

Planned (sponsor's estimate)

Start

Jan 6, 2026

Primary completion

Dec 2028

Study completion Apr 2029

Sponsor

Lead sponsor
Gemma BiotherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 2 weeks, up to 12 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

GB221 is a gene therapy that delivers a working SMN1 gene to the motor neurons of people with spinal muscular atrophy (SMA) Type 1. This study will evaluate the safety, tolerability and efficacy of GB221 in two groups: 1. participants aged from 2 weeks to younger than 12 months presenting with symptoms of SMA Type 1 who have never received a treatment OR are receiving the drug risdiplam 2. participants aged from 2 weeks to younger than 5 months who are at risk of developing SMA Type 1 (presymptomatic) and have never received treatment OR are receiving the drug risdiplam.

Conditions

  • Spinal Muscular Atrophy Type I

Interventions

  • GB221Biological

    GB221

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events (AEs) and serious adverse events (SAEs) at Grade 3 or higher as characterized by CTCAEv5.0Time frame: Up to 18 months across multiple visits
  2. Number of Participants with Clinically Significant Changes in Physical FunctionsTime frame: Up to 18 months across multiple visits
  3. Number of Participants with Clinically Significant Changes in Neurological FunctionsTime frame: Up to 18 months across multiple visits
  4. Number of Participants with Clinically Significant Changes in Vital signsTime frame: Up to 18 months across multiple visits
  5. Change in electrocardiogram resultsTime frame: Up to 18 months across multiple visits
  6. Change in serum cardiac troponin I levelsTime frame: Up to 18 months across multiple visits
  7. Number of Participants with Clinically Significant Laboratory Abnormalities as Measured Using Hematology, Chemistry and Coagulation TestsTime frame: Up to 18 months across multiple visits
  8. Number of Participants with Clinically Significant Laboratory Abnormalities as Measured Using Urine and CSF TestsTime frame: Up to 18 months across multiple visits
  9. Change in markers of immunogenicityTime frame: Up to 18 months across multiple visits

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.